Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers
Authors:
Open Access
- 21 October 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Metabolic reprogramming is a hallmark of cancer initiation, progression, and relapse. From the initial observation that cancer cells preferentially ferment glucose to lactate, termed the Warburg effect, to emerging evidence indicating that metabolic heterogeneity and mitochondrial metabolism are also important for tumor growth, the complex mechanisms driving cancer metabolism remain vastly unknown. These unique shifts in metabolism must be further investigated in order to identify unique therapeutic targets for individuals afflicted by this aggressive disease. Although novel therapies have been developed to target metabolic vulnerabilities in a variety of cancer models, only limited efficacy has been achieved. In particular, lung cancer metabolism has remained relatively understudied and underutilized for the advancement of therapeutic strategies, however recent evidence suggests that lung cancers have unique metabolic preferences of their own. This review aims to provide an overview of essential metabolic mechanisms and potential therapeutic agents in order to increase evidence of targeted metabolic inhibition for the treatment of lung cancer, where novel therapeutics are desperately needed.Keywords
This publication has 143 references indexed in Scilit:
- LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug PhenforminCancer Cell, 2013
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- PTEN Tumor Suppressor Network in PI3K-Akt Pathway ControlGenes & Cancer, 2010
- The Classic: The Chemical Constitution of Respiration FermentClinical Orthopaedics and Related Research, 2010
- Cancer as a metabolic diseaseNutrition & Metabolism, 2010
- Clinical Relevance of KRAS in Human CancersJournal of Biomedicine and Biotechnology, 2010
- HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancerNature, 2009
- The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1RJournal of Biological Chemistry, 2009
- Pyruvate Dehydrogenase Complex Activity Controls Metabolic and Malignant Phenotype in Cancer CellsJournal of Biological Chemistry, 2008
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)New England Journal of Medicine, 1948